Vedanta Biosciences taps Big Pharma vet Jeffrey Silber as CMO; Robert Doebele leaves behind teaching post at Colorado to focus on CSO job at Rain Therapeutics
→ A Big Pharma vet has joined Cambridge, MA upstart Vedanta Biosciences to help develop and expand on its microbiome-derived bacteria portfolio.
Jeffrey Silber signed on as CMO of Vedanta after 4 years at EMD Serono as their SVP, global clinical development. Silber worked his way through the ranks at Merck in the late 1990s, eventually becoming their VP and therapeutic area head, vaccine clinical research. And after 16 years at the pharma giant, Silber moved on to AbbVie to be their VP, strategic portfolio development.